B-intervention	0	7	Nigella
I-intervention	8	14	sativa
I-intervention	15	16	L
I-intervention	16	17	.
O	18	21	for
O	22	32	prevention
O	33	35	of
B-condition	36	41	acute
I-condition	42	51	radiation
I-condition	52	62	dermatitis
O	63	65	in
O	66	72	breast
O	73	79	cancer
O	79	80	:
O	81	82	A
O	83	93	randomized
O	93	94	,
O	95	101	double
O	101	102	-
O	102	107	blind
O	107	108	,
O	109	116	placebo
O	116	117	-
O	117	127	controlled
O	127	128	,
O	129	137	clinical
O	138	143	trial
O	143	144	.

O	145	148	The
O	149	156	present
O	157	162	study
O	163	168	aimed
O	169	171	to
O	172	180	evaluate
O	181	184	the
O	185	198	effectiveness
O	199	201	of
O	202	209	Nigella
O	210	216	sativa
O	217	218	L
O	218	219	.

O	220	221	(
O	221	222	N
O	222	223	.
O	224	230	sativa
O	230	231	)
O	232	239	extract
O	240	242	on
O	243	253	preventing
O	254	257	the
O	258	267	incidence
O	268	270	of
O	271	276	acute
O	277	286	radiation
O	287	297	dermatitis
O	298	299	(
O	299	302	ARD
O	302	303	)
O	304	306	in
O	307	313	breast
O	314	320	cancer
O	321	329	patients
O	329	330	.

B-total-participants	331	336	Sixty
I-total-participants	336	337	-
I-total-participants	337	340	two
B-eligibility	341	347	breast
I-eligibility	348	354	cancer
I-eligibility	355	363	patients
I-eligibility	364	374	undergoing
I-eligibility	375	387	radiotherapy
I-eligibility	388	389	(
I-eligibility	389	391	RT
I-eligibility	391	392	)
O	393	397	were
O	398	406	randomly
O	407	415	assigned
O	416	418	to
O	419	427	receiveN
O	427	428	.
O	429	435	sativa
O	436	437	5
O	437	438	%
O	439	442	gel
O	443	445	or
B-control	446	453	placebo
O	453	454	.

O	455	463	Patients
O	464	468	were
O	469	479	instructed
O	480	482	to
O	483	488	apply
O	489	492	the
O	493	504	medications
O	505	510	twice
O	511	516	daily
O	517	523	during
O	524	526	RT
O	527	533	period
O	533	534	.

O	535	538	The
O	539	547	severity
O	548	550	of
O	551	554	ARD
O	554	555	,
O	556	559	the
O	560	569	incidence
O	570	572	of
O	573	578	moist
O	579	591	desquamation
O	591	592	,
O	593	598	worst
O	599	610	experienced
O	611	615	pain
O	615	616	,
O	617	620	and
O	621	625	skin
O	625	626	-
O	626	633	related
O	634	641	quality
O	642	644	of
O	645	649	life
O	650	651	(
O	651	656	SRQOL
O	656	657	)
O	658	664	scores
O	665	669	were
O	670	678	assessed
O	679	685	weekly
O	686	692	during
O	693	695	RT
O	695	696	.

O	697	705	Patients
O	706	709	who
O	710	714	were
O	715	722	treated
O	723	727	with
O	728	731	the
O	732	733	N
O	733	734	.
O	735	741	sativa
O	742	745	gel
O	746	755	developed
O	756	759	ARD
O	760	773	significantly
O	774	778	less
O	779	789	frequently
O	790	798	compared
O	799	801	to
O	802	807	those
O	808	811	who
O	812	816	used
O	817	820	the
O	821	828	placebo
O	829	830	(
O	830	831	p
O	832	833	<
O	834	835	0
O	835	836	.
O	836	838	05
O	839	842	for
O	843	846	all
O	847	852	weeks
O	853	859	except
O	860	864	week
O	865	866	2
O	866	867	,
O	868	869	p
O	870	871	=
O	872	873	0
O	873	874	.
O	874	876	36
O	876	877	)
O	877	878	.

O	879	882	The
B-outcome	883	892	incidence
I-outcome	893	897	time
I-outcome	898	900	of
I-outcome	901	906	grade
I-outcome	907	908	2
I-outcome	909	912	and
I-outcome	913	914	3
O	915	917	of
O	918	927	Radiation
O	928	935	Therapy
O	936	944	Oncology
O	945	950	Group
O	951	954	and
O	955	958	the
O	959	967	European
O	968	980	Organization
O	981	984	for
O	985	993	Research
O	994	997	and
O	998	1007	Treatment
O	1008	1010	of
O	1011	1017	Cancer
O	1018	1019	(
O	1019	1023	RTOG
O	1023	1024	/
O	1024	1029	EORTC
O	1029	1030	)
O	1031	1039	toxicity
O	1040	1043	was
O	1044	1053	prolonged
O	1054	1067	significantly
O	1068	1072	with
O	1073	1074	N
O	1074	1075	.
O	1076	1082	sativa
O	1083	1086	gel
O	1087	1089	as
O	1090	1098	compared
O	1099	1101	to
O	1102	1109	placebo
O	1110	1111	(
B-iv-cont-mean	1111	1113	35
O	1114	1116	vs
O	1116	1117	.
B-cv-cont-mean	1118	1120	29
I-cv-cont-mean	1121	1125	days
O	1125	1126	,
O	1127	1128	p
O	1129	1130	=
O	1131	1132	0
O	1132	1133	.
O	1133	1135	00
O	1136	1139	and
B-iv-cont-mean	1140	1142	42
O	1143	1145	vs
O	1145	1146	.
B-cv-cont-mean	1147	1149	40
I-cv-cont-mean	1150	1154	days
O	1154	1155	,
O	1156	1157	p
O	1158	1159	=
O	1160	1161	0
O	1161	1162	.
O	1162	1164	01
O	1164	1165	,
O	1166	1178	respectively
O	1178	1179	)
O	1179	1180	.

O	1181	1192	Furthermore
O	1192	1193	,
O	1194	1197	the
B-outcome	1198	1208	occurrence
I-outcome	1209	1211	of
I-outcome	1212	1217	moist
I-outcome	1218	1230	desquamation
O	1231	1234	was
O	1235	1242	delayed
O	1243	1245	in
O	1246	1249	the
O	1250	1251	N
O	1251	1252	.
O	1253	1259	sativa
O	1260	1263	gel
O	1264	1269	group
O	1270	1278	compared
O	1279	1283	with
O	1284	1287	the
O	1288	1295	placebo
O	1296	1301	group
O	1302	1303	(
B-iv-cont-mean	1303	1305	37
O	1306	1308	vs
O	1308	1309	.
B-cv-cont-mean	1310	1312	33
I-cv-cont-mean	1313	1317	days
O	1317	1318	,
O	1319	1320	p
O	1321	1322	=
O	1323	1324	0
O	1324	1325	.
O	1325	1327	01
O	1327	1328	)
O	1328	1329	.

O	1330	1333	The
B-outcome	1334	1338	mean
I-outcome	1339	1344	score
I-outcome	1345	1347	of
I-outcome	1348	1351	the
I-outcome	1352	1357	worst
I-outcome	1358	1362	pain
O	1363	1367	that
O	1368	1376	patients
O	1377	1388	experienced
O	1389	1391	in
O	1392	1395	the
O	1396	1403	placebo
O	1404	1409	group
O	1410	1413	was
O	1414	1427	significantly
O	1428	1434	higher
O	1435	1439	than
O	1440	1444	that
O	1445	1447	of
O	1448	1451	the
O	1452	1453	N
O	1453	1454	.
O	1455	1461	sativa
O	1462	1465	gel
O	1466	1471	group
O	1472	1474	at
O	1475	1479	week
O	1480	1481	3
O	1482	1483	(
B-iv-cont-mean	1483	1484	2
I-iv-cont-mean	1484	1485	.
I-iv-cont-mean	1485	1486	5
O	1487	1488	±
B-iv-cont-sd	1489	1490	0
I-iv-cont-sd	1490	1491	.
I-iv-cont-sd	1491	1492	5
O	1493	1495	vs
O	1495	1496	.
B-cv-cont-mean	1497	1498	1
I-cv-cont-mean	1498	1499	.
I-cv-cont-mean	1499	1500	2
O	1501	1502	±
B-cv-cont-sd	1503	1504	0
I-cv-cont-sd	1504	1505	.
I-cv-cont-sd	1505	1506	3
O	1506	1507	,
O	1508	1509	p
O	1510	1511	<
O	1512	1513	0
O	1513	1514	.
O	1514	1516	05
O	1516	1517	)
O	1517	1518	.

O	1519	1530	Nonetheless
O	1530	1531	,
O	1532	1535	the
O	1536	1547	application
O	1548	1550	of
O	1551	1552	N
O	1552	1553	.
O	1554	1560	sativa
O	1561	1564	gel
O	1565	1568	had
O	1569	1571	no
O	1572	1583	significant
B-outcome	1584	1590	effect
I-outcome	1591	1593	on
I-outcome	1594	1597	the
I-outcome	1598	1603	SRQOL
O	1604	1606	of
O	1607	1615	patients
O	1616	1618	at
O	1619	1622	any
O	1623	1627	week
O	1627	1628	.

O	1629	1630	N
O	1630	1631	.
O	1632	1638	sativa
O	1639	1646	extract
O	1647	1660	significantly
O	1661	1670	decreases
O	1671	1674	the
O	1675	1683	severity
O	1684	1686	of
O	1687	1690	ARD
O	1691	1694	and
O	1695	1701	delays
O	1702	1705	the
O	1706	1711	onset
O	1712	1714	of
O	1715	1720	moist
O	1721	1733	desquamation
O	1734	1736	in
O	1737	1743	breast
O	1744	1750	cancer
O	1751	1759	patients
O	1759	1760	.
